Investigating Structure-Activity Relationships Of SL11 To Develop A Better Prostate Cancer Diagnostic

Prostate cancer is now the second leading cause of cancer death in American men. Since many of the diagnostics either have high false results or risky, it’s important to have better diagnostics and earlier diagnosis of prostate cancer. Aberrant glycosylation is a hallmark of cancer. When cancer occurs, aberrant glycosylation occurs, therefore, glycosylation patterns may provide information about different cancer types and metastatic potential. In order to study and use these glycosylation patterns, the boronic acid functionalized synthetic lectins that can interact with glycans have been developed. The work described here focuses on 1) the structure activities of synthetic lectins (SLs), especially SL11 which is selected against the prostate cancer cell line PC3, for developing a structure-activity relationship for the SL11 with both purified glycoproteins and proteins from prostate cell lines, 2) study the ability of an array of SLs to classify prostate cancer cell lines and colon cancer cell lines